#Prenatal and New-born Genetic Testing future market | Explore Tumblr posts and blogs

themedicalstate · 4 years ago

Photo

23 and Baby

By Tanya Lewis (Scientific American). Image Credit: Enan Liang.

We now have the ability to screen for thousands of genetic diseases in newborns. That may not always be the healthy thing to do

Mitchell Gorby came into this world around 3 P.M. on August 9, 2019, at Balboa Naval Hospital in San Diego. The baby seemed healthy, and his parents, Tiffany and Rylan, were thrilled. But a few hours later a nurse noticed that Mitchell seemed lethargic and never cried, and monitors indicated that his body was not getting enough oxygen. Mitchell was rushed to the neonatal intensive care unit at nearby Rady Children’s Hospital, where tests revealed that oxygen wasn’t bonding to the molecule that carries it through the blood, hemoglobin, and his red blood cells were dying off. He wasn’t nursing, so the hospital put in a feeding tube. Mitchell’s doctor ordered CT and brain scans and tested for infectious diseases—but she could not figure out what was wrong with him. As a last resort, she suggested sequencing Mitchell’s genome.

The results from Stephen Kingsmore’s laboratory at the Rady Children’s Institute for Genomic Medicine came back within about 48 hours. Mitchell had a rare genetic mutation known as hemoglobin Toms River, which prevents oxygen from bonding to the proteins in fetal red blood cells. The mutation—named after the New Jersey hometown of the first patient identified with the problem in 2011—affects only fetal hemoglobin; babies start making healthy adult hemoglobin within a few months. Doctors just had to keep Mitchell alive until that happened. Rady neonatologist Jeanne Carroll says that “having his whole genome allowed us to know the starting point” for treatment. She and Mitchell’s team of physicians prescribed a series of blood transfusions, and the baby improved rapidly. In just under a month he was strong enough to go home.

For children like Mitchell who are born with a genetic disease, it used to take years to get a diagnosis, and by then it often was too late. Now, however, advances in the speed of genetic sequencing and steeply falling costs have made it possible to screen for hundreds or even thousands of childhood-onset genetic diseases. Within the past year or so a few dozen hospitals have started offering the ability to rapidly sequence a newborn’s genome to help diagnose a life-threatening condition soon after birth. Researchers are studying whether such sequencing should be offered to all newborns as part of standard health screening. And companies such as Sema4 and BabyGenes are now marketing 23andMe-style direct-to-consumer tests to parents simply seeking to know more about the health of their baby. Prenatal and newborn genetic sequencing is expected to grow to an $11.2-billion industry by 2027, up from a $4-billion market in 2018.

Proponents say that genetic testing of newborns can help diagnose a life-threatening childhood-onset disease in urgent cases and could dramatically increase the number of genetic conditions all babies are screened for at birth, enabling earlier diagnosis and treatment. It could also inform parents of conditions they could pass on to future children or of their own risk of adult-onset diseases. Genetic testing could detect hundreds or even thousands of diseases, an order of magnitude more than current heel-stick blood tests—which all babies born in the U.S. undergo at birth—or confirm results from such a test.

But others caution that genetic tests may do more harm than good. They could miss some diseases that heel-stick testing can detect and produce false positives for others, causing anxiety and leading to unnecessary follow-up testing. Sequencing children’s DNA also raises issues of consent and the prospect of genetic discrimination.

Regardless of these concerns, newborn genetic testing is already here, and it is likely to become only more common. But is the technology sophisticated enough to be truly useful for most babies? And are families—and society—ready for that information?

In the 1960s microbiologist Robert Guthrie developed a test for phenylketonuria (PKU), a genetic disorder that causes the amino acid phenylalanine to build up in the body. PKU is easily treated with a phenylalanine-restricted diet, but without intervention it can cause brain damage and mental disabilities. Within a few years other U.S. states required that Guthrie’s test be administered to newborns, and tests for other conditions were soon to follow. By the mid-1980s most states had mandatory screening programs. In 2002 the federal government asked the American College of Medical Genetics to develop guidelines for newborn screening, which culminated in the Recommended Universal Screening Panel, a set of 35 core conditions and 25 secondary ones that are treatable. Most states now test for a subset of these conditions.

There are roughly 14,000 known genetic diseases in humans, ranging from childhood-onset diseases such as PKU and congenital heart disease to adult-onset conditions such as Huntington’s disease and heritable forms of cancer. Some childhood diseases, such as PKU, are treatable if caught early. Heel-stick tests look for only a tiny fraction of these diseases, hence the appeal of genetic testing.

In the early 2010s researchers at the National Institute of Child Health and Human Development and the National Human Genome Research Institute launched a program, called NSIGHT (short for Newborn Sequencing in Genomic Medicine and Public Health), to explore the risks and benefits of DNA screening of newborns. Rady’s Kingsmore led one of four projects funded by NSIGHT, which explored the use of rapid, whole-genome sequencing in extremely sick newborns suspected of having a genetic disease.

Standard sequencing can take weeks, but using a rapid sequencing method and software that compared the genome with the patient’s disease characteristics, Kingsmore’s team could get a genetic diagnosis back in as little as a day or two. For these babies, hours or days can be the difference between life and death or severe disability. The first of two trials led by Kingsmore took place from 2014 to 2016 at Children’s Mercy Hospital in Kansas City. The second ran from 2017 to 2019 at Rady Children’s. Within the past year the group has started offering newborn sequencing at 23 hospitals around the country, and lawmakers from California have introduced federal legislation to cover the cost of sequencing critically ill babies through Medicaid. As of last November, Kingsmore and his colleagues had sequenced more than 1,100 babies with suspected genetic diseases. About one in three of them received a diagnosis that identified an illness, and one in four had their existing treatment changed as a result.

Mitchell Gorby was one of those sequenced at Rady (but not as part of NSIGHT). Carroll, the Rady neonatologist, says the information “helped us more confidently give him more transfusions and hold off on other testing.” It is possible Mitchell may have survived and outgrown his disorder without the test and diagnosis. But in other cases, sequencing has very likely saved lives. Moreover, sequencing probably significantly reduced the diagnostic odyssey such children have to take, Kingsmore says.

Extremely sick babies are not the only ones who could benefit from genetic testing. Another NSIGHT project investigated whether sequencing could also be used in clinical settings to screen newborns with no obvious signs of disease.

For this study, called the BabySeq Project, Robert Green of Brigham and Women’s Hospital, Alan Beggs of Harvard Medical School and their colleagues recruited families and randomly assigned half of them to have their babies’ genomes sequenced. They developed a list of about 1,500 genes that were highly associated with diseases that begin in childhood or adolescence, then returned information about a subset of those genes to the families. The goal was to do the most comprehensive testing possible—to see anything and everything that could be discovered about gene-based risks. Last January the group reported sequencing results from 159 newborns—mostly healthy babies but also some ill ones in the neonatal ICU. The scientists found that 9.4 percent of the healthy group were at risk of developing a childhood-onset disease that was not known from their medical or family history, and 88 percent were carriers for recessive diseases.

So was the testing worth it for parents? A mother named Natalie, who requested we use only her first name out of concern for her family’s privacy, has a son who was enrolled in BabySeq. Natalie, who is a physician and lives in Washington, D.C., admits she felt some nervousness about the testing. “Whenever you have the chance to learn about the health of your child, there’s an opportunity for anxiety,” she says. But overall, she and her husband were comfortable with the project. “Because they were looking at only genetic defects that affect childhood and only illnesses that had some preventive measures, we felt it could potentially be useful,” she says.

Fortunately, the results of tests on her son, Russell, did not turn up any childhood-onset genetic disorders. The exams did indicate that he may be a carrier for a recessive metabolic disorder called Gaucher disease, but the sequencing of this gene is particularly prone to error, so he will need follow-up testing to confirm. For other families, the benefits of sequencing were more clear-cut: one child had a disorder—missed by standard screening—that makes the body unable to recycle a vitamin called biotin; the condition can cause coma and death if left untreated, but it can easily be treated by supplementation.

Although BabySeq was initially focused only on childhood-onset disorders, one baby in the study was found to carry a variant of the BRCA2 gene, which is associated with a high risk of breast and other cancers, so the researchers asked parents for permission to inform them of the risk of adult-onset disorders if they chose. Natalie and her husband opted not to receive this information but said they would leave it up to Russell if he wanted to be tested when he was older. “We felt it should be our son’s decision,” Natalie says.

Because of its complexity and cost, BabySeq was never intended to be a feasible addition to standard newborn screening. “We have not tried to advocate for this in clinical practice,” Green of Brigham and Women’s says. But sequencing tests are no longer confined to clinical practice. Several companies now offer direct-to-consumer DNA tests for newborns. The firm Sema4 sells a test for $379 that it says screens for more than 190 genetic conditions that can occur before the age of 10 and that can be treated with medication, diet or other interventions. The company gives results to parents in a genetic-counseling session about four to six weeks after the test. Sema4’s CEO, Eric Schadt, says the test can detect disease-related genetic variants with 99 percent accuracy. Sema4 only reports results for diseases that have a greater than 80 percent penetrance—the proportion of people with a genetic variant who end up developing the disease. It also discloses information about the child’s sensitivity to certain drugs, although the U.S. Food and Drug Administration has recently been pressuring companies not to make such information available, because it says that it has not reviewed the tests and that they may not be backed up by clinical evidence.

Another company, BabyGenes, offers a test that scours 100 genes for more than 72 conditions. It is offered in the form of either a cheek swab or dried-blood spot test and retails for $349.

Schadt admits Sema4 doesn’t know whether the kind of testing it offers leads to an overall benefit for patients, although he says the company is doing studies to find out. There are reasons to wonder. The accuracy of these tests in detecting disease is still uncertain. In a third NSIGHT project, led by Jennifer Puck, Barbara Koenig and Pui-Yan Kwok of the University of California, San Francisco, researchers sequenced the DNA of dried spots of blood left over from newborn heel-stick tests (California has kept all its blood spots since the early 1980s). Although the sequencing did detect some genetic conditions that the standard newborn screening panel does not test for, it missed some of those that standard screening caught. And it flagged a lot of genetic variants of unknown significance, Puck says: “Newborn screening is very different from having a sick individual in front of you for whom you’re trying to arrive at a diagnosis.”

When combined with the standard screening, DNA testing did reduce the number of false positives, however. Puck thinks sequencing could be an add-on to standard screening when there’s an abnormal result, but she doesn’t think it should be used to screen all healthy babies. “We’re just not at the point where we can interpret the sequence with sufficient predictive value to say ‘yes’ or ‘no,’ this is a disease or not,” she says.

Another issue that concerns physicians and medical ethicists is the possibility that genetic testing will cause unnecessary anxiety for parents about diseases that may appear later in life or never show up at all. “When it comes to genetic information about your child, a lot of people aren’t in a position to well interpret what the results mean,” says Nita Farahany, a professor of law and philosophy at Duke University School of Law, who is an expert in genetics and bioethics. “If they’re told their child has a four times greater risk [of some condition], but the population risk is 1 percent, how do they treat their children?” There is already a shortage of genetic counselors in the U.S., so there would not be enough people to help parents understand their child’s genetic results.

Then there’s the issue of privacy. If the child’s genetic information is stored on file, who has access to it? If the information becomes public, it could lead to discrimination by employers or insurance companies. The Genetic Information Nondiscrimination Act (GINA), passed in 2008, prohibits such discrimination. But GINA does not apply to employers with fewer than 15 employees and does not cover insurance for long-term care, life or disability. It also does not apply to people employed and insured by the military’s Tricare system, such as Rylan Gorby. When his son’s genome was sequenced, researchers also obtained permission to sequence Rylan’s genome, to determine if he was a carrier for the rare hemoglobin condition. Because it manifests itself only in childhood, Gorby decided taking the test was worth the risk of possible discrimination.

Cost is another consideration. Clinical sequencing is still about $500 to $800, and interpretation can be upward of $1,000, according to Brigham and Women’s Green. For families who can’t afford health insurance, this is out of reach. Some experts have also raised concerns that genetic testing could lead to a lot of follow-up testing with specialists, which could overburden an already resource-strapped health care system. If sequencing turns out to save money in the long run, insurance companies may cover it, but there’s no guarantee.

Yet another problem is that the majority of the sequencing to date has been done in babies whose families are well-off and white, raising concerns that this could become the province of only the privileged. And the racial homogeneity could skew the results: diseases more prevalent in Caucasian individuals could be overrepresented in test panels, whereas illnesses more common in racial minorities may be underrepresented. (New medical data projects intend to address this disparity [see “All of Us”].)

The U.C.S.F. NSIGHT project included a working group that investigated some of these ethical and policy issues, which culminated in a 2018 report by the Hastings Center, a bioethics nonprofit in Garrison, N.Y. The report concluded that newborn sequencing has many benefits in helping diagnose sick babies and could expand the number of conditions that meet the stringent newborn screening criteria. But using genome sequencing as a replacement for newborn screening is “at best premature,” the authors say, and direct-to-consumer sequencing should not be used for diagnosis or screening purposes.

Barbara Koenig, a professor of medical anthropology and bioethics at U.C.S.F. and one of the report’s co-authors, underscores the fact that sequencing, while promising, is not yet mature enough to be routinely used to screen healthy children. “This is not a technology that’s ready for prime time for use in healthy infants,” Koenig says.

Despite these concerns, the era of newborn sequencing is now upon us, and the practice will likely become more widespread as costs come down and the results become more accurate and useful. In the meantime, the risks and benefits of sequencing must be weighed on an individual basis. Extremely sick newborns are a completely different case from apparently healthy children of worried parents susceptible to marketing from genetic-testing firms.

For Mitchell Gorby, sequencing was certainly worth it. Two months after leaving the hospital, he is doing fine and has doubled his weight. His parents are settling into their new routine, somewhat sleep-deprived, but happy to be home with their healthy baby boy.

#science #medicine #biotech #genetics #health #medblr #academia

43 notes · View notes

leftcomputerpost · 3 years ago

Text

Zellweger Spectrum Disorder Market Will Escalate Rapidly in the Near Future

Zellweger Spectrum Disorder Market Overview

According to the latest research by Future Market Insights, the Zellweger Spectrum Disorder market will witness growth during 2021-2031.

Zellweger spectrum disorder consists of Heimler Syndrome, Infantile Refsum Disease and Neonatal Adrenoleukodystrophy. With new advances coming up in genomics, novel ways to treat and manage ZSD in a way that gives the minimum discomfort to the victims of this disorder are being researched and trialled.

These will further boost the market during the forecast period.

Being a rare disease, not much was known about ZSD. But now with soaring research investments, better clinical understanding is beginning to build.

This will boost early diagnosis of the disorder which help in mapping appropriate treatment plans. Ultimately, all of these factors will amount to a global market growth.

What is Driving Demand for Zellweger Spectrum Disorder Market

Zellweger spectrum disorders is group of inherited autosomal genetic conditions where most of the organs of the human body are affected.

This disease happens due to mutation of a specific gene called as PEX-gene which makes it defective, showing early signs like high forehead, muscular hypotonia, seizures, vision and hearing difficulties, etc. soon after birth. Therefore, the rising genomics research an important factor to boost its market.

This disorder is pretty rare as 1 in 50,000 new-borns get affected due to ZSD.

The novel corona virus has swept the entire globe and hence in finding a cure against it has boosted the research and development faction.

Aggressive research in finding answers towards the previously less researched and rare diseases like zellweger spectrum disorder is gaining popularity as healthcare professionals are wanting to be entirely prepared for any similar occurrence in the future. Making it one of the most important driving factors which will contribute in its growth.

For more insights into the market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-13942

Genetic Counselling for Zellweger Spectrum Disorders

"At birth, there is 25% chance of the sibling of new-born getting affected and 50% chance of that individual being a carrier with no symptoms and 25% chance of being asymptomatic and not a carrier." says the study done by University of Washington. So, pertaining to this, testing of relatives of the identified affected individual can be undertaken.

Also counselling of these probable carrier individuals to do a prenatal DNA testing in order to plan a timely management of zellweger spectrum disorders can be done.

As, prevalence of this disorder cannot be avoided. Early detection of this disorder will certainly help in early treatment and thus boosting the market.

U.S. and Canada Zellweger Spectrum Disorder Market

With state-of-the-art healthcare as well as ceaseless researches going on foreshadows that U.S will dominate the North American market.

Presence of a mandate for zellweger screening test for new-born babies added to availability of highly developed diagnostic equipments will aid U.S in dominating the zellweger spectrum disorder market.

Rising initiatives for detection, prevention and treatment of this disorders is helping in boosting the awareness of this disorder.

Europe Zellweger Spectrum Disorder Market

The second dominant market in zellweger spectrum disorders will be Europe. New-born testing for ZSD is taking a grip after US making it mandatory.

Dedicated research with various collaborations are also underway in order to ensure proper testing facilities and kits are available for the new-born testing and various other verticals for management of this disorder.

Furthermore, presence of players in like Centogene N V (Germany), Asper Biogene LLC (Estonia). in the region is likely to augment ZSD market growth.

For any queries linked with the report, ask an analyst

https://www.futuremarketinsights.com/ask-question/rep-gb-13942

Who are the key Manufacturing and Supplying Companies in Zellweger Spectrum Disorder Market

Key Players:

Invitae

Blueprint Genetics Oy

Centogene N V

Gene Dx Inc.

Asper Biogene LLC

Eugene labs

GE Healthcare

Philips Healthcare

Siemens Healthcare

Trivitron Healthcare

Care Stream Healthcare

AGFA Healthcare

Shimadzu

Hitachi Medical.

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.

The report provides an in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments.

The report also maps the qualitative impact of various market factors on market segments and geographies.

Zellweger Spectrum Disorder Market Report Highlights:

Detailed overview of the parent market

Changing market dynamics in the industry

In-depth market segmentation

Historical, current and projected market size in terms of volume and value

Recent industry trends and developments

Competitive landscape

Strategies of key players and products offered

Potential and niche segments, geographical regions exhibiting promising growth

A neutral perspective on market performance

Must-have information for market players to sustain and enhance their market footprint

Request a Complete TOC of this Report with figures: https://www.futuremarketinsights.com/toc/rep-gb-13942

NOTE - All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of the company.

Key Segments

By Treatment Type:

Audiological

Ophthalmological

Orthopaedic

Paediatric

Neurological

Surgical

By Diagnostic Tests:

Blood test

Urine test

Ultrasound

Genetic tests

By End User:

Hospitals

Clinics

Health Centres

Diagnostic Centres

Genetic Testing Laboratories

By Region:

North America

Latin America

Europe

South Asia

East Asia

Oceania

Middle East & Africa

About FMI: Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact Us: Mr. Debashish Roy Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A, Jumeirah Lakes Towers, Dubai, United Arab Emirates MARKET ACCESS DMCC Initiative For Sales Enquiries: [email protected] For Media Enquiries: [email protected] Website: https://www.futuremarketinsights.com

0 notes

industryupdates · 3 years ago

Text

Genomics Market is Expected to Reach USD 54.9 Billion by 2027

Rising government funding to support research projects, increasing incidence of cancer, and expanding applications of NGS in cancer research are fueling the demand of the Genomics market. The global Genomics market was valued at USD 19.9 billion in 2020, and it is expected to reach USD 54.9 billion by 2027, with a CAGR of 15.5%, during the forecast period.

Genomics refers to the distinctive field of biology which majorly focuses on structure, function, evolution, mapping, and editing of genomes. The genome is a complete set of a DNA in an organism’s body which certainly involves all its genes. The study of genomics aims at collectively categorizing and quantifying all organisms’ genes.

Key determinants driving the growth of this market comprise rising incidence of cancer and growing applications of NGS in the cancer research letter, extending public funding to support gene projects, the entry of new players and start-ups in the gene market and its application areas. The scientific community has attempted to reduce severity and genetic susceptibility to SARS-CoV-2 infection by combining research efforts with the help of existing genetic databases. Polyatomic approaches and genome-wide association studies (GWAS) were used to uncover biological networks and underlying common variations in host-host interactions pathogens. Likewise, genome-derived data, such as ABO blood groups, polygenic risk scores (PRS), and HLA haplogroups, can be used to interpret complications, likelihood resistance and susceptibility of COVID-19.

Get a Sample Copy of Report @ https://www.alltheresearch.com/sample-request/718

In addition, bio banks that link electronic health records (EHRs) to genomic data can be used to study the impact of genomic factors on the clinical course of infected patients by SARS-CoV-2. Soon years, prenatal genetic screening programs are expected to expand at a significant rate. Certainly, these programs will help pregnant women identify chromosomal abnormalities in their babies. Additionally, it is expected that within the next 10 years, each new-born’s genome will be sequenced and stored in an electronic medical record. Assessing the future commercial potential of genetics in newborn screening programs, emerging companies such as Counsyl and Natera have launched various genetic tests to maintain their competitive edge in the market. However, factors such as the high cost of genomic equipment, lack of trained professionals, and lack of space to secure large amounts of sequence data can pose challenges to the genomics market growth.

Developments in the personalized medicine market are expected to offer a wide range of opportunities for players active in the genomics market. Many pharmaceutical companies are investing in personalized drug research. Personalized medicine enables healthcare professionals to identify the exact needs of their patients, and then prescribe medications accordingly. This method guarantees better results of care. In addition, advances in gene therapy are expected to have the potential to replace traditional drugs and surgery by allowing doctors to treat the disease by inserting a gene into the patient's cells.

Key Findings:

Based on deliverable, the consumables segment is expected to have the highest market share during the forecast period.

Based on technology, sequencing segment is growing with a high CAGR during the forecast period.

Based on the application, the drug discovery and development segment is expected to grow with the highest CAGR during the forecast period.

On the basis of end user, the genomics market has been segmented into hospitals & clinics, research centers and academic & government institutes, pharmaceutical & biotechnology companies, and other. Amongst which hospitals and clinics segment is anticipated to hold the largest market share by both volume and value in the forecast period.

Geographically, the North America region held a significant portion of the global Genomics market in 2020 and is expected to maintain its dominance during the forecast period.

Recent News:

In January 2021, in order to track the exposure and pervasiveness of the novel strains of SARS-CoV-2, Illumina, Inc. and helix have announced a partnership to expand and solidify the national surveillance infrastructure in the U.S. with the help from CDC. Two of the companies will get together to combine Illumina's sequencing technology and expertise and Helix's national COVID-19 test track, that will benefit country’s surveillances to keep track of SARS-CoV-2 variants.

· In February 2018, MGI is a member of BGI group which is a global leader in genomics industry had signed an agreement with prime distributors in Colombia, Brazil, Mexico, Argentina, Ecuador, and Peru to expand its business in DNA sequencing and laboratory automation products available in Latin Americ

Company Profiles and Competitive Intelligence

F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Oxford Nanopore Technologies, Danaher Corporation, Agilent Technologies, Inc., Beijing Genomics Institute (BGI), GE Healthcare, Pacific Biosciences of California, Inc., Myriad Genetics, Inc.

About AlltheResearch: AllTheResearch was formed with the aim of making market research a significant tool for managing breakthroughs in the industry. As a leading market research provider, the firm empowers its global clients with business-critical research solutions. The outcome of our study of numerous companies that rely on market research and consulting data for their decision-making made us realize, that it’s not just sheer data-points, but the right analysis that creates a difference.

For all your Research needs, reach out to us at: 39180 Liberty Street Suite 110, Fremont, CA 94538, USA Contact Person: Rohit B. Email: [email protected] US: 1-888-691-6870

#Genomics Market #Genomics

0 notes

dpiresearchofficial · 5 years ago

Link

Global Non-Invasive Prenatal Testing(NIPT) market is anticipated to grow over US$ 2.5 Billion by 2025 with an impressive double-digit growth rate in the forecast period 2018 – 2025.

The market is driven by the number of factors such as high incidence rate of babies born with down syndrome, no risk of miscarriage with NIPT test, shifting trend towards childbearing at advanced maternal age (35 years or older), rising focus on reimbursement for NIPT and increasing preference for non-invasive techniques over invasive methods.

“Global Non-Invasive Prenatal Testing Market: Demand, Insights, Analysis, Opportunities, Growth Potential and Forecast 2018 – 2025” presents an in-depth assessment of the Global Non-Invasive Prenatal Testing (NIPT) market dynamics, opportunities, future roadmap, competitive landscape and discusses major trends. The report offers the most up-to-date industry data on the actual market situation and future outlook for Global Non-Invasive Prenatal Testing (NIPT). The research includes historic data from 2014 to 2017 and forecasts until 2025.

The report contains a granular analysis of the present industry situations, market demands, reveal facts on the market size, NIPT test volume, revenues and provides forecasts through 2025. A comprehensive analysis has been done on the market share of NIPT tests and Countries-based market. The report also includes an assessment of comparative test analysis by companies. Additionally, the report includes insights into the Global perspectives on clinical adoption of NIPT. Key trends in terms of collaboration, partnership, merger & acquisition, venture capital investment, distribution, and licensing agreement are analyzed with details. The report also explores detailed description of growth drivers and inhibitors of the Global Non-Invasive Prenatal Testing (NIPT) market.

The report concludes with the profiles of major players in the Global Non-Invasive Prenatal Testing (NIPT) market. The key market players are evaluated on various parameters such as company overview, NIPT test portfolios, and the latest development and trends of the Non-Invasive Prenatal Testing (NIPT) market.

KEY FINDINGS:

United States is anticipated to be the most attractive market in the Global Non-Invasive Prenatal Testing(NIPT) market

China NIPT test market is set to cross USD 400 Million by 2025

Panorama test accounted for the highest share in Global Non-Invasive Prenatal Testing(NIPT) market

Verifi test has the second highest revenue share in the Global Non-Invasive Prenatal Testing(NIPT) market

Rising focus on Reimbursement for NIPT test will revolutionize the market

Two–Child policy is likely to boost China NIPT market

The Major Companies Dominating this Market for its Products, Services and Continuous Product Developments are:

Illumina, Natera, Sequenom Laboratories (LabCorp), Ariosa Diagnostics (Roche), BGI Diagnosis Co. Ltd, Berry Genomics, Quest Diagnostics, LifeCodexx AG, Premaitha Health, NIPD Genetics

Major and Promising Non-Invasive Prenatal Testing (NIPT) Covered Under This Report are:

Panorama, MaterniT21 PLUS, Harmony, Verifi, NIFTY, IONA, PrenaTest, Bambni, Veracity and Other Tests

Major Countries Analyzed Under This Report are:

United States, China, Japan, India, Brazil, Australia, New Zealand, United Kingdom, Germany, Italy, Spain, France, Switzerland, Sweden, Belgium, Russia, Turkey, Netherland, Poland, Armenia, Moldova, Denmark and Rest of the Countries.

The Latest Industry Data Included in this Report:

Global Non–Invasive Prenatal Testing Market Volume & Future Trends (2014 – 2025)

Global Non–Invasive Prenatal Testing Market Revenue & Future Trends (2014 – 2025)

Global Non–Invasive Prenatal Testing Market Share and Y–o–Y Growth (%)

Market Share Analysis, by Test, 2014 – 2025 (%)

Market Share Analysis, by Major Countries, 2014 – 2025 (%)

Global Non–Invasive Prenatal Testing Market, By Test (Volume and Value),2011 – 2025

Global Non–Invasive Prenatal Testing Market, By Geography (Volume and Value),2014 – 2025

Non–Invasive Prenatal Testing(NIPT) Comparative Analysis – By Test

Major Deals in Global Non–Invasive Prenatal Testing Market

Global Perspectives on Clinical Adoption of NIPT

Global Non–Invasive Prenatal Testing Market Drivers and Inhibitors

Key Companies Analysis

#nipt #testing #global #market #research #report #dpiresearch

0 notes

fitnesshealthyoga-blog · 6 years ago

Photo

New Post has been published on https://fitnesshealthyoga.com/prenatal-expanded-carrier-screening-tests-can-be-difficult-to-interpret-shots/

Prenatal Expanded Carrier Screening Tests Can Be Difficult To Interpret : Shots

Shara and Robert Watkins hold their 5-month-old daughter, Kaiya, in their home in San Mateo, Calif., just after she had woken up from an afternoon nap.

Lindsey Moore/KQED

hide caption

toggle caption

Lindsey Moore/KQED

Shara and Robert Watkins hold their 5-month-old daughter, Kaiya, in their home in San Mateo, Calif., just after she had woken up from an afternoon nap.

Lindsey Moore/KQED

It wasn’t hard for Shara Watkins to get pregnant. It was hard for her to stay pregnant.

In 2016, she was devastated by two miscarriages. With the help of several medications, she successfully carried a child last year.

Shara and her husband, Robert, were elated when she reached her second trimester, the phase when the highest risk of miscarriage subsides.

Unfortunately the San Mateo, Calif., couple’s struggles continued.

Shara spent four months of her pregnancy on bedrest. When their doctor offered extensive genetic testing to check the health of their fetus, the couple leaped at the opportunity. Shara had a history of rare disease in her family.

“I had a high-risk pregnancy, and there had been a lot of complications prior to this,” says Shara. “And, so I just wanted to have all the information that I could.”

Glut of information available to expecting parents

In the past, doctors may have screened parents for a few suspect diseases common to their specific ethnicity or family history. But now a growing number of companies offer extensive panels testing for hundreds of rare diseases.

“Over the last 10 to 20 years the number of genetic disorders that we are able to test for has exploded,” says Dr. Mary Norton, a prenatal geneticist at University of California, San Francisco.

Silicon Valley is a hotbed for companies vying for the business of concerned future parents. The prenatal genetic testing industry is projected to grow nearly 30 percent over the next five years.

A wide variety of tests are now available to screen both fetus and parents. One option that’s rapidly growing in popularity is called an expanded carrier screening.

About a dozen lab companies, most based in the San Francisco Bay Area, can scan a patient’s blood or saliva for hundreds of conditions that their child could inherit.

A perfectly healthy parent can pass along an autosomal recessive disease like cystic fibrosis or Tay-Sachs, if their partner is also a carrier for the disease. When both parents have a mutated version of the same gene, then their child is at an increased risk for developing a condition.

“In these types of diseases, 80 percent of the time there’s no family history,” says Jim Goldberg, chief medical officer of Myriad Women’s Health. Norton agrees that family history is not a very sensitive screening tool.

The ideal time to take a carrier screening is prior to conception because in vitro fertilization is still a possibility.

If both parents are found to be carriers of the same disease, IVF allows doctors to ensure a healthy fertilized egg by genetically screening the embryos before conception.

The tests must be prescribed by a doctor and screening panels vary widely in price. For example, a call to the customer service line for Myriad Genetics’ lab in South San Francisco led to a price quote of $1,599 for patients who don’t have insurance.

Gifty Hammond prepares DNA samples at Myriad Genetics lab in South San Francisco.

Lesley McClurg/KQED

hide caption

toggle caption

Lesley McClurg/KQED

Gifty Hammond prepares DNA samples at Myriad Genetics lab in South San Francisco.

Lesley McClurg/KQED

But if you pay within 45 days, the price drops to $349. Shara and Robert paid about $600 out of pocket for their two screening panels from a Bay Area company called Natera. The company charged their insurance about $3,200 for both tests.

Does knowing more help?

When Shara and Rob’s doctor emailed their tests results, the couple was alarmed because their physician suggested they see a genetic counselor to help them interpret the report.

“This new landscape is complicated and it’s beyond the ability for most OB-GYN’s to really understand it themselves and explain it well,” says UCSF’s Norton.

It appeared the Watkin’s baby could inherit spinal muscular atrophy, or SMA, a potentially fatal disease. The couple hadn’t discussed what they would do if their child was unhealthy.

“I called Rob in pure hysterics on my way to work,” says Shara.

“When I got the call in my office she was crying,” recalls Rob. “We were both in kind of a panic mode immediately.”

Rob and Shara spent the day poring over page after page of testing results, and then subsequent days searching the Internet for answers.

“The test results give you kind of these alerts on the first page like you’re a carrier for this, your carrier for this,” Shara says. “It’s definitely not clear. I mean, if it had been clear we wouldn’t have ever gone into full panic mode.”

Find an expert

Although Shara and Rob could have sought free counseling from one of Natera’s genetic counselors, they chose an unaffiliated expert. They booked the first available appointment at Stanford Children’s Health. Stanford billed $642 to Shara’s insurance for the consultation. Her plan paid $352.

“They came to us with this information not knowing what it meant, not knowing what the risks were and not understanding the implications,” says Meg Homeyer, a genetic counselor at Stanford. “Plus, the language is difficult to interpret and sometimes can sound alarmist.”

As it turns out, Shara, Rob and their doctor thought their baby’s risk of SMA was a lot higher than it was. The report says they were at an increased carrier risk, but that isn’t the same thing as being an actual carrier for the disease.

“It was much more lower, more like 3,500,” says Homeyer as she thumbed through the test results. Yet, even though Rob and Shara’s worst fears didn’t play out, they still lost sleep at night wondering if their child could be the 1 in 3,500.

Making sense of risks

Homeyer says she frequently sees parents agonize over how to feel, or whether to act on abstract numbers.

“They will not know whether a baby is 100 percent healthy until birth,” says Homeyer. “In the meantime they’re trying not to worry about the risks but they can’t help it.”

Homeyer says the value of a test is dependent on the values of an individual couple.

“There’s the family that will want every possible test available,” says Homeyer. “They’ll want no stone unturned because their tolerance for risk is low. There are other families where this information in pregnancy isn’t useful for them.”

Like families who would not seek further diagnostic testing, or potentially terminate a pregnancy regardless of testing results.

“We often have people who say, ‘I wish I had never started down this path,’ ” says Norton. “Although I don’t think people can really anticipate how they’ll feel until they get there.”

One test leads to the next

For those who choose to do a carrier screening, the worst-case scenario is their child has a 1 in 4 chance of inheriting an autosomal recessive condition. Further diagnostic invasive testing like an amniocentesis is necessary to confirm the possibility. Fortunately, care for rare diseases has improved dramatically in recent years.

“Many more of these conditions are treatable after birth,” says Norton. “And treatment starting right at the time of birth may improve the outcomes. In some cases we can even start treatment during pregnancy.”

Norton says the advent of more advanced testing stirred a lot of fear among practitioners that abortion rates would simultaneously rise, but that’s not what preliminary studies are showing.

Why scanning for more diseases isn’t always better

If you’re the type of parent who does want as much information as possible, you may be inclined to take the most comprehensive test on the market. However, Aleks Rajkovic, chief genomics officer at UCSF, cautions families attracted to extensive panels.

“A lot of them are overkill,” says Rajkovic. “Some panels are testing for very rare disorders that have only been seen in a single family, so the likelihood of a client ever actually having the variation is infinitely small.”

Plus, he says extremely rare disease are usually not well studied or understood, so it’s very hard for doctors to offer helpful information about what a prognosis could entail.

Fortunately Shara’s little girl, Kaiya, is a healthy 5-month-old. When asked if Shara would go back and take the genetic test again, she pauses, but then nods yes.

Even though she spent months fretting over the tiny possibility her child wasn’t ok, she says the anxiety she dealt with was better than not knowing anything all. Her advice to future parents is think carefully about whether more information will, for them, be reassuring or just another thing to worry about.

Norton agrees. She hopes families focus on a key fact: 97 percent of babies are born perfectly healthy.

Source link

#current health news usa #health insurance news usa #health news united states #Health News

0 notes

nickyshukla1 · 4 years ago

Text

Global NON‚ÄÌINVASIVE PRENATAL TESTING Market - Global Demand, Sales, Consumption and Forecasts 2018-2025

Summary - A new market study, titled “Global NON‚ÄÌINVASIVE PRENATAL TESTING Market Analysis, Trends and Opportunities 2018-2025” has been featured on WiseGuyReports

Europe Non–Invasive Prenatal Testing market is set to touch US$ 500 Million by 2025. The market is driven by number of factors such as high incidence rate of babies born with down syndrome, no risk of miscarriage with NIPT test, shifting trend towards child bearing at advanced maternal age (35 years or older), rising focus on reimbursement for NIPT and increasing preference for non–invasive techniques over invasive methods. “Europe Non–Invasive Prenatal Testing Market Research Report 2018” presents an in–depth assessment of the Europe non–invasive prenatal testing market dynamics, opportunities, future roadmap, competitive landscape and discusses major trends. The report offers the most up–to–date industry data on the market situation and future outlook. The research includes historic data from 2014 to 2017 and forecasts until 2025. The report contains a granular analysis of the present industry situations, market demands, reveal facts on the market size, NIPT test volume, revenues and provides forecasts through 2025. A comprehensive analysis has been done on market share of country–based market. The report also includes assessment of comparative test analysis by companies. Key trends in terms of collaboration, partnership, merger & acquisition, venture capital investment, distribution and licensing agreement are analyzed with details. The report also explores detailed description of growth drivers and inhibitors of the Europe non–invasive prenatal testing market.

ALSO READ: http://heraldkeeper.com/news/europe-non-invasive-prenatal-testing-market-covid-19-impact-on-industry-analysis-size-share-growth-trends-forecasts-2025-506062.html

The superior geographic segments are identified in the report which studies NIPT test consumed and market revenue of the 15 countries. The countries included in this report are United Kingdom, Germany, Italy, Spain, France, Switzerland, Sweden, Belgium, Russia, Turkey, Netherland, Poland, Armenia, Moldova, Denmark from 2014 to 2017 and forecasts to 2025. The report concludes with the profiles of major players in the Europe non–invasive prenatal testing market. The key market players are evaluated on various parameters such as company overview, NIPT test portfolios and latest development and trends of the non–invasive prenatal testing market. The major European companies dominating this market for its products, services and continuous product developments are: Ariosa Diagnostics (Roche), LifeCodexx AG, Premaitha Health PLC and NIPD Genetics Major and Promising NIPT Test Available in the European Region are: • Panorama • MaterniT21 PLUS • Harmony • Verifi • NIFTY • IONA • PrenaTest • Veracity

FOR MORE DETAILS: https://www.wiseguyreports.com/reports/3449812-europe-non-invasive-prenatal-testing-market-research-report-2018

About Us:

Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.

NORAH TRENT

[email protected]

Ph: +162-825-80070 (US)

Ph: +44 203 500 2763 (UK)

#NON‚ÄÌINVASIVE PRENATAL TESTING Market

0 notes

marketreasearch · 4 years ago

Text

Global Hereditary Testing Market to Witness a Pronounce Growth During 2027

Hereditary testing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to hereditary testing market.

Market Analysis and Insights: Global Hereditary Testing Market

Hereditary testing market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account toUSD 9.31 billion by 2027 growing at a CAGR of 6.10% in the above-mentioned forecast period. The accelerating generative hereditary health scope is one of the key market drivers.

The major players covered in the hereditary testing marketreport are F. Hoffmann-La Roche Ltd, Abbott, Amgen Inc., ELITechGroup, GW Pharmaceuticals plc, Thermo Fisher Scientific Inc., Pfizer Inc., PerkinElmer Inc., AutoGenomics, Bio-Rad Laboratories, Inc., BioMarin, Sarepta Therapeutics,Amicus Therapeutics, Inc., Alexion Pharmaceuticals, Inc., Sanofi, Takeda Pharmaceutical Company Limited, Vertex Pharmaceuticals Incorporated,among other domestic and global players. Market share data is available for global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa(MEA) and South America separately. DBMR analystsunderstand competitive strengths and provide competitive analysis for each competitor separately.

Get Sample Report + All Related Graphs & Charts @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-hereditary-testing-market

The harmonious upsurge in trade for new-born screening has pointed to an improvement in the commerce of DNA experiment equipment. Progressing keen-sightedness of new-born screening crosswise the earth is moreover supporting in earnings growth. Reformations in genetic experimentation guidelines beget headed to the formation of a multigene board trial for genetic melanoma into clinical application. Continuous advancements in the distribution model are expected to profit the genetic examination business. Technological amendments are performing a significant function in the market growth by enhancing their delivery assistance and progressing the effectiveness of the technology implied. Organizations are adopting a cloud-based administration design to compose bioinformatics technology accessible for employment by other labs. Expense and preservation solicitudes encountered by users of the analysis and the dearth of adequate supervision of the experiments can act as a restraint for the market.

This hereditary testing market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on Data Bridge Market Research hereditary testing market contact us for an Analyst Brief,our team will help you take an informed market decision to achieve market growth.

Grab Your Report at an Impressive 30% Discount! Please click Here @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-hereditary-testing-market

Global Hereditary Testing Market Scope and Market Size

Hereditary testing marketis segmented onthe basis of hereditary cancer testing and hereditary non-cancer testing. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Based onhereditary cancer testing, the hereditary testing marketis segmented into lung cancer, breast cancer, colorectal cancer, cervical cancer, ovarian cancer, prostate cancer, stomach/gastric cancer, melanoma, sarcoma, uterine cancer, pancreatic cancer, and others.

Based on hereditary non-cancer testing, the hereditary testing market is segmented intogenetic tests, newborn genetic screening, preimplantation genetic diagnosis & screening, non-invasive prenatal testing (NIPT) & carrier screening tests. Genetic tests are further sub-segmented into cardiac diseases, rare diseases, and other diseases.

Hereditary Testing Market Country Level Analysis

Hereditary testing marketis analysed and market size insights and trends are provided by country,hereditary cancer testing and hereditary non-cancer testing as referenced above.

The countries covered in the hereditary testing marketreport are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa(MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the hereditary testing market due to the high prevalence of breast cancer patients, and entrance of the key market players and strong healthcare foundation.

The country section of the hereditary testing marketreport also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

For More Insights Get Detailed TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-hereditary-testing-market

Healthcare Infrastructure growth Installed base and New Technology Penetration

Hereditary testing marketalso provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for hereditary testing market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the hereditary testing market. The data is available for historic period 2010 to 2018.

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today! Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email @ [email protected]

0 notes

databridgemarketresearchblog · 4 years ago

Text

Gaucher Disease Market 2020 Industry Research, Share, Trend, Industry Size, Price, Future Analysis, Regional Outlook to 2027 Research Report | DBMR Updates

This Gaucher Disease Market research document predicts the size of the market with information on key vendor revenues, development of the industry by upstream & downstream, industry progress, key companies, along with type segment & market application. This market study takes into account a market attractiveness analysis, where each segment is benchmarked based on its market size, growth rate, and general attractiveness. Another major section of this Gaucher Disease Market report is the competitive landscape which provides a clear insight into the market share analysis and actions of key industry players. Quality and transparency is strictly maintained while carrying out research studies to offer an exceptional market research document for your niche.

Get Exclusive Sample Copy of This Report Here https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-gaucher-disease-market

All the data of this market report is exceptionally useful to the clients and businesses for making decisions related to revenue, investment, import, export and consumption. To meet the strategic as well as specific needs of the organization or business, a comprehensive market research document such as this Gaucher Disease Market report, has to be in place. Geographical scope of the products is also carried out comprehensively for the major global areas such as Asia, North America, South America, and Africa which helps define strategies for the product distribution in those areas. Competitive landscape is explored in terms of product range, strategies, and future prospects of the key players of the Healthcare industry.

Market Analysis: Besides target market information, DBMR also provides information about your competitor, your customers, products etc. A few techniques we use are: Customer analysis Competitor analysis Risk analysis Product research Advertising research E-mail survey and many more…

Gaucher disease market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market is growing at a healthy CAGR in the above-mentioned forecast period. Rising prevalence of gaucher disease worldwide and emerging markets are the factors responsible for the growth of this market.

The major players covered in the gaucher disease market are Actelion Pharmaceuticals Ltd, Amerigen Pharmaceuticals, Inc., Genzyme Corporation F. Hoffmann-La Roche Ltd, Novo Nordisk A/S, Eli Lilly and Company among others.

To Get This Report at an Attractive Cost, Click Here https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-gaucher-disease-market

Market Analysis and Insights: Global Gaucher Disease Market

Growing cases of lysosomal storage related disorders drives the gaucher disease market. Due to low levels of glucocerebrosidase enzyme, increased gene mutation disorders and family history with lysosomal storage disorders will boost up the gaucher disease market growth. Moreover, continuous clinical trials going on rare disorders and increased demand of drugs for the treatment of rare disorders will boost up the global gaucher disease market. However, due to rare disorders difficulty in clinical trials and stringent FDA guidelines for the approval of new treatment or drugs may hamper the global gaucher disease market.

Gaucher disease is an inherited disorder resulting build-up of certain fatty substance in certain organ, mainly in liver, bone marrow and spleen. It is the most common lysosomal storage disorders. Due to the low level of glucocerebrosidase an enzyme that breaks down the fatty chemical in the body known as glucocerebroside. Gaucher cells are normal scavenger cells known as macrophages that become full of unprocessed glucocerebroside. These unprocessed gaucher cells accumulate primarily in the sleep, liver and bone marrow and causes serious orang dysfunction and inflammation. Each pregnant female has a 1 in 4 chance that the baby will be born with the disease. People with Gaucher disease carrier status do not have signs or symptoms. Symptoms of gaucher disease include skeletal abnormalities, blood disorders and abdominal complaints.

This gaucher disease market report provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographical expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Gaucher Disease Market Scope and Market Size

The gaucher disease market is segmented on the basis of type, diagnosis, treatment, route of administration, end-users and distribution channel.

On the basis of type, the gaucher disease market is segmented into gaucher disease type 1, gaucher disease type 2, gaucher disease type 3 and others

On the basis of diagnosis, the gaucher disease market is segmented into physical exam, blood tests, imaging tests, preconception screening & prenatal testing and others

On the basis of treatment, the gaucher disease market is segmented surgery, medication and other. Medication segment further divided into enzyme replacement therapy, osteoporosis drugs, glucosylceramide synthase inhibitors and others. Surgery segment further segmented into spleen removal, bone-marrow transplant, spleen removal and others

Route of administration segment of gaucher disease market is segmented into oral, parenteral and others

On the basis of end-users, the gaucher disease market is segmented into hospitals, specialty clinics and others

On the basis of distribution channel, gaucher disease market has also been segmented into hospital pharmacy, retail pharmacy others

Key Development for the Gaucher Disease:

In April 2018, Amerigen Pharmaceuticals, Inc., “MIGLUSTAT” approved by the USFDA for the treatment of gaucher disease with 100mg capsule. MIGLUSTAT is beneficial for patients with mild to moderate type 1 Gaucher disease for whom enzyme replacement therapy is not a therapeutic option. MIGLUSTAT holds two granted the U.S. patents, US9079856B2 and US8802155B1, one pertaining to a method of synthesis for miglustat and the other for a crystalline form of the same.

Gaucher Disease Market Country Level Analysis

Gaucher disease market is analysed and market size information is provided by country, type, diagnosis, treatment, route of administration, end-users and distribution channel as referenced above.

The countries covered in the gaucher disease market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific in Asia-Pacific, U.A.E, Egypt, Saudi Arabia, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.

North America holds the largest market share due to increased rate of prenatal screening. Europe is considered second largest market for gaucher disease due to increase prevalence of genetic disorders and increased awareness of inherited disorders.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Gaucher disease market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Gaucher Disease Market Share Analysis

Gaucher disease market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to gaucher disease market.

Customization Available: Global Gaucher Disease Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.

Read Complete Details with TOC Here https://www.databridgemarketresearch.com/toc/?dbmr=global-gaucher-disease-market

About Data Bridge Market Research:

Data Bridge Market Research is a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475 Mail: [email protected]

#Gaucher Disease Market

0 notes

cindy893 · 5 years ago

Text

Prenatal and New-born Genetic Testing Market SWOT Analysis by Emerging Growth Factors from 2020-2026 | Agilent Technologies, Inc., Bio-Rad Laboratories, Inc.

We bring you the latest and the most updated report titled Global Prenatal and New-born Genetic Testing Market which our internal expert analysts have forecasted to substantially grow at a fairly greater CAGR over the forecast period 2020 to 2026.

Description:

Stable and upgraded with our accredited policy of delivering the supreme quality research content from across the world to our thriving list of potential and esteemed clients. This is yet another market report which is fabricated to match up to their expectations. The market research report on Prenatal and New-born Genetic Testing Market is a closely incorporated study.

Request Sample Report at: http://www.marketresearchglobe.com/request-sample/1246415

This Report will Benefit You How!

The research report integrates the analysis of the market and also forecasts the Global Prenatal and New-born Genetic Testing Market Research Report on a worldwide level. The report forecasts the growth in terms of revenue on all three – global, regional and country levels. It endows analysis of the latest trends and potential opportunities of the market are every segment in the forecast period. Our professional analysts with proven credibility between the research fraternities have minutely analyzed the overall revenue and sales production of this market. This research study grasps a market – in which the segments are studies based on their size of the market and overall growth rate.

Moreover, this market report embraces the analysis of numerous profiles of fundamental market manufacturers of Prenatal and New-born Genetic Testing market.

Agilent Technologies, Inc.

Bio-Rad Laboratories, Inc.

Natera, Inc.

Illumina, Inc.

Ariosa Diagnostics

Perkin Elmer

Verinata Health

Sequenom, Inc.

Types is divided into:

PCR

FISH

aCGH

NIPT

MSS

Applications is divided into:

Hospital

Clinic

Others

The complete market segments of this report are meticulously considered based on many Countries. Furthermore, this market report sections the worldwide market into its primary countries which chiefly backs to the complete growth, considering the market share, revenue, consumption and sales, and growth of Prenatal and New-born Genetic Testing in these countries during the forecast period 2020 to 2026.

Significant Regions covered in this report:

North America, Europe, China, Japan, Southeast Asia, India, Central & South America

Check Discount for Report: http://www.marketresearchglobe.com/check-discount/1246415

In conclusion, the market research report renders comprehending insight based on several types and applications. The product types are further collected with the focus area being on the price, revenue, growth rate, market share, etc. Similarly, based on the applications, the report aims the growth rate, market share of Prenatal and New-born Genetic Testing in each application.

Which are the Key Questions to buy the Prenatal and New-born Genetic Testing report?

What will be analyzing center capabilities and pieces of the overall industry of key players in the Prenatal and New-born Genetic Testing and thoroughly profiling them?

What are the Unveiling significant possibilities and openings accessible in the Prenatal and New-born Genetic Testing advertise?

What will be researching the market based future possibilities, development patterns, and Prenatal and New-born Genetic Testing elements?

What are the market size of driving fragments and sub-sections of the Prenatal and New-born Genetic Testing ?

What are the Prenatal and New-born Genetic Testing market openings and methods adopted and seen by the players?

Enquire Additional Concerning the Report at: http://www.marketresearchglobe.com/send-an-enquiry/1246415

Customization of this Report: This Prenatal and New-born Genetic Testing report could be customized to the customer's requirements. Please contact our sales professional ([email protected]), we will ensure you obtain the report which works for your needs.

0 notes

rohinic123-blog · 5 years ago

Text

Prenatal and New-born Genetic Testing Market to Observe Strong Development by 2019

The growing awareness among consumers regarding chromosome abnormalities in the fetus has presented high-value opportunities to the prenatal and genetic testing service providers. Companies providing prenatal and newborn genetic testing techniques are making continuous efforts to improve the existing technologies and present the market with new breakthrough technologies.

The leading vendors of prenatal and newborn genetic tests are using these developments as a stepping stone for growth. The prenatal and newborn genetic testing market comprises top four companies who held a share of 53% in 2013; the market is expected to show steady growth until 2019. Sequenom Inc. was reported as the company with the largest share followed by Verinata Health, Bio-Rad Laboratories, and Agilent Technologies. The growth of the prenatal and newborn genetic market depends on how vendors capitalize on the potential market in the emerging countries, mainly Asia and Africa.

Planning To Lay Down Future Strategy? Request Brochure Of Prenatal and New-born Genetic Testing Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1744

Advancements in Prenatal and Newborn Genetic Testing Technology to Provide Competitive Advantage to Vendors

All companies in the prenatal and newborn genetic testing industry, primarily use the next generation sequencing technique (NGS) to detect chromosomal anomalies. However, various leading companies use different techniques such as MPSS and target sequencing to detect other abnormalities namely Down Syndrome, Edward Syndrome, and Patau Syndrome. For instance, a Cyprus-based start-up introduced a technique based on the methylated DNA immune precipitation (MeDIP) application. This technique has been reported to be more efficient than the already existing NGS technology. Thus, the rise in new technologies will provide an advantage to vendors of prenatal and newborn genetic tests as they enhance accuracy along with safety of mothers by detecting chromosome abnormalities.

The average maternal age is increasing in developed countries which is leading to the heightened risk of fetal abnormalities among new mothers. The demand for prenatal and newborn genetic tests is expected to rise as a result of the chromosomal anomalies caused due to increased maternal age.

To Obtain All-Inclusive Information On Forecast Analysis Of Prenatal and New-born Genetic Testing Market , Request A Discount

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=1744

Falling Fertility Rate among Women above 30 Years of Age to Hamper Growth of Prenatal and Newborn Genetic Testing Industry

Recent studies have evidenced that due to harsh environmental factors and changing lifestyles, the ovarian reserve of women is decreasing after the age of 30. The decrease in ovarian reserve also makes women more unfertile after 30, leading to a rise in infertility rate. The increasing infertility rate among women is likely to hinder the growth of the prenatal and newborn genetic market.

On the technological front, diagnostic methods are preferred over screening methods as they are more accurate for the detection of chromosome anomalies. The global market for diagnostic methods is expected to grow at a steady rate and reach US$2633.6 mn by 2019. Apart from this, the entry of new players is expected to increase competition in future, however the untapped market is expected to keep the competitive rivalry at a low level in several regions. North America is reported to the lead the global prenatal and newborn genetic industry followed by Europe in second place. The market for prenatal and newborn genetic testing was worth US$3,854.9 mn in 2015 and is anticipated to reach US$8,377.4 mn by 2019.

More Trending Reports by Transparency Market Research –

Culture Media Market –

https://www.prnewswire.com/news-releases/culture-media-market-to-rise-at-7-7-cagr-during-2017-2025--launch-of-new-pharmaceuticals-to-drive-growth-says-tmr-300789727.html

Cardiac Surgery Instruments Market –

https://www.prnewswire.com/news-releases/cardiac-surgery-instruments-market-to-hit-us1-412-7-million-with-increasing-threat-of-cardiovascular-diseases-says-tmr-300790695.html

0 notes

coolluminaryland-blog1 · 5 years ago

Text

Next Generation Sequencing for Non Invasive Prenatal Testing Market to Develop Rapidly by 2024

Non-invasive prenatal testing is gradually being accepted by pregnant women with high-risk for screening common fetal chromosomal aneuploidies such as Edward’s syndrome (trisomy 18), Down syndrome (trisomy 21), Turner syndrome (monosomy X) and Patau syndrome (trisomy 13). Accuracy, safety, and non-invasiveness are the key factors credited to the acceptance of these tests amongst gynecologists and expecting mothers related to invasive tests such as amniocentesis and chorionic villus sampling (CVS). MaterniT21 was the first NIPT introduced in October 2011 by Sequenom, Inc. of the U.S. Since then, it has been the leader of the market, accounting for the biggest share in terms of volume as well as revenue. However, BGI’s NIFTY is likely to overtake MaterniT21 PLUS in terms of volume in the global market. Sequenom, Inc. is likely to maintain its leadership position in North America through 2024. Panorama, verifi, informaSeq, Harmony, VisibiliT, BambniTest and PrenaTest are the other commercially available NIPTs for detecting chromosomal abnormalities.

Read Report Overview: https://www.transparencymarketresearch.com/next-generation-sequencing-for-non-invasive-prenatal-testing-market.html

Next generation sequencing is used in the sequencing technologies that immensely parallelize the DNA sequencing process rather than limited few fragments or to a single of DNA. The next generation sequencing (NGS) technology permits rapid sequencing and yields thousands and millions of sequences in single run using next generation sequencers. Such technologies have been rapidly developing owing to the constant demand for high-throughput sequencers which incline to lesser the cost of DNA sequencing.

According to the Department of Biology, University of Copenhagen, There are almost 7000 rare diseases that have been reported globally. Although most of them occur with an incidence of less than one in 2000, in total around 6% of the population suffers from rare diseases. These rare diseases are mostly caused by changes in genes, which is presently lack of effective treatment. The quick advancement of next generation sequencing technology boosts the discovery of new causative gene for these rare diseases, as well as the genetic diagnosis in clinic practice.

Request Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=14135

The innovation of cell-free fetal DNA, coupling with next generation sequencing, makes NIPT possible for rare diseases. However, for most of the current routine prenatal genetic testing for rare diseases require collection of fetal samples through an invasive process, which sometimes might lead to maternal anxiety, or even lead to miscarriage. Hence, developing an effective method to perform noninvasive prenatal test (NIPT) for rare diseases is the crucial challenge to inhibit birth defect in the future.

The exponential progress of the NIPT market is supported by factors such as no risk of miscarriage with NIPT, high incidence rate of babies born with Down syndrome, and shifting trend toward child bearing at advanced maternal age. Maternal age is closely related to the risk of developing a fetus with chromosomal abnormalities; hence, rising maternal age is likely to contribute to the increasing incidence of babies born with chromosomal aneuploidies.

Request For TOC : https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=14135

Geographically, the market for non-invasive prenatal testing products has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Europe is the biggest market with more number of cases followed by North America. Adoption in Asia pacific is lesser due to less awareness. North America is expected to grow at highest CAGR in the forecast period. According to Down Syndrome Education (DSE), the incidence rate for Down syndrome is one in every 830 children births in the U.S., while the incidence rate is one in every 920 babies born in Europe, indicating a large potential consumer base for NIPT. Conventional invasive prenatal genetic tests such as chorionic villus sampling (CVS) and amniocentesis are related with the risk of miscarriage; hence, these are being replaced with new non-invasive prenatal tests. These new NIPTs are based on the analysis of cell-free DNA floating in the maternal plasma and pose no risk of miscarriage.

Some of the market players in this industry are., Illumina, Inc., Agilent Technologies, Inc, Biomatters, Ltd., BGI (Beijing Genomics Institute), Pacific Biosciences, Oxford Nanorpore Technologies, Ltd., Dnastar, Inc., Life Technologies Corporation, EMC Corporation, Genomatix Software GMBH, Ocimum Biosolutions, Ltd., Macrogen, Inc., Partek Incorporated, Qiagen N.V., Perkinelmer, Inc., Knome, Inc. and GATC biotech AG.

0 notes

supershadystudentsweetsfan-blog · 6 years ago

Text

Genetic Testing Industry and Global 2025 Foresight Report

The global Genetic Testing Market is majorly driven by the importance of early disease diagnosis and prevention, growing need for personalized medicine, increasing application of genetic testing in oncology and increasing awareness on the importance of prognosis and predictive screening. The market is affected by the high costs involved in the genetic testing development and lack of skilled professionals.

Download Sample Copy of Genetic Testing Market @ https://www.orbisresearch.com/contacts/request-sample/2588617

Government Initiatives impacting the Genetic Testing market:

Promoting the awareness through the government is one of the major factors driving the genetic testing market globally. Government is taking certain initiatives on launching a large number of PGx test & drugs, controlling the increasing level of genetic disorders, and integrating advanced technologies to meet the needs of patients.

The US Government is contributing to the development of a growing and comprehensive genetic testing market that has the capability coordinating the collective efforts of the various regulators to achieve the strategic objectives.

Top Players:

The major companies in the genetic testing market include Ranomics, Biocartis SA, Applied Biosystems, Inc., and Celera Group, Daan Diagnostics Ltd, Genentech, Inc., Eastern Biotech, DNAFit, Perkinelmer, Inc., Qiagen N.V., DNA CONSULTANTS and Sorenson Genomics, LLC.

Check Discount @ https://www.orbisresearch.com/contacts/discount/2588617

Key Highlights:

In January 2015, the Obama Administration has launched a plan known as “Precision Medicine Initiative” to accumulate genetic data, analyze people’s full genetic makeup, and identify genetic causes for diseases. This proposal is advantageous as genetic testing turns out to be less expensive. personalized genomic medicine will also advance as government and private forces simultaneously identify, explore, and promote attractively and patient benefiting investment opportunities.

In Feb 2016, Health Minister in the UK allocated a new investment to ensure that patients from Northern Ireland have full access to new genetic tests for rare diseases. In 2015, the UK Genetic Testing Network introduced new tests alone for conditions such as metabolic disorders, hepatology, neurology, and ophthalmology. According to the report produced by the UK Rare Disease Forum England, Scotland, Wales and Northern Ireland are progressing to meet the recommendations of the UK Strategy for Rare Diseases.

Market Segmentation-

A genetic Testing market is segmented by types such as Carrier Testing, Diagnostic Testing, Forensic Testing, New Born Screening, Prenatal Screening, Predictive and Presymptomatic Screening, and Others.The report segments the sample by Blood, Hair, Saliva, Tumours, and Others. Based on a type of technology, the market is segmented into Biochemical Genetic Testing, Chromosomal Genetic Testing, Molecular Genetic Testing. The report segments the geographies by regions, which include North America, South America, Europe, Asia Pacific and RoW.North America has the largest market for genetic testing. India, China, and Australia are expected to have a large market in the near future.

Enquiry before Buying @ https://www.orbisresearch.com/contacts/enquiry-before-buying/2588617

About Us:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Hector Costello

Senior Manager – Client Engagements

4144N Central Expressway,

Suite 600, Dallas,

Texas - 75204, U.S.A.

Phone No.: +1 (214) 884-6817; +9120641 01019

Email id: [email protected]

#Genetic Testing Industry

0 notes

priyankaganguly-blog · 6 years ago

Text

Non-invasive Prenatal Testing (NIPT) Market – Future Performance Improvements 2025

Global Non-invasive Prenatal Testing Market: Snapshot

The global market for non-invasive prenatal testing is expected to grow at a significant pace in the next few years. The increasing risk of chromosomal abnormalities with the rising maternal age is one of the key factors anticipated to encourage the growth of the global market in the next few years. The rising prevalence for non-invasive techniques over the invasive ones is another key factor, which is predicted to accelerate the growth of the overall market in the coming few years. In addition to this, the key players in the market are focusing on development of new products, thus generating promising growth opportunities across the globe.

Request Sample Copy of the Report @

https://www.tmrresearch.com/sample/sample?flag=B&rep_id=2198

The increasing number of programs that are focusing on creating an awareness among people regarding the non-invasive prenatal testing is anticipated to encourage the growth of the global market in the next few years. On the flip side, the lack of skilled professionals is considered as one of the major factors, which is predicted to restrict the growth of the global market in the next few years. Moreover, the reliability of these tests results, particularly in obese women is one of the key challenges for the growth of the market. Nonetheless, the untapped developing markets is projected to offer potential growth opportunities for the market players in the next few years.

The presence of several leading players and the availability of high-tech medical infrastructure are the key factors that are anticipated to encourage the growth of the non-invasive prenatal testing market across North America in the next few years. Some of the key players operating in the glaobl market are Sequenom, Inc., Illumina, Inc. (Verinata Health, Inc.), Ariosa Diagnostics, Natera, Inc., LabCorp, BGI Health, LifeCodexx AG, and Berry Genomics. These players are estimated to focus on expansion of their product portfolio and enhance their market penetration in the coming few years.

Global Non-invasive Prenatal Testing (NIPT) Market: Overview

The growing preference for non-invasive techniques over invasive surgeries is one of the key growth drivers for the global non-invasive prenatal testing (NIPT) market. In addition to this number of babies born with Down syndrome, XYY syndrome, Turner, and Klinefelter is increasing, boosting the growth of the market. These chromosomal aneuploidies occur as a result of infertility, reproductive loss, and language development delays and can be detected and diagnosed by non-invasive prenatal testing. Thus, NIPT enables the detection of fatal chromosomal aneuploidies through the analysis of the cell-free DNA of fetuses. NIPT makes use of ultrasononography and serum screening.

Request TOC of the Report @

https://www.tmrresearch.com/sample/sample?flag=T&rep_id=2198

Global Non-invasive Prenatal Testing (NIPT) Market: Key Trends

One in every 830 child births in the U.S. suffers from the Down syndrome, as per Down Syndrome Education (DSE). In Europe, the incidence rate for Down syndrome is one in every 920 babies. Thus, there exists a large potential consumer base for NIPT. An increasing number of people are preferring NIPT because chorionic villus sampling (CVS) and amniocentesis, which are the traditional invasive prenatal genetic tests can result in the risk of miscarriage. Non-invasive prenatal testing however, analyze the cell-free DNA, which floats in the maternal plasma. Thus, no risk of miscarriage exists in the use of NIPT methods. A growing number of doctors are opting for non-invasive prenatal testing that make use of cell-free circulating DNA in the maternal serum.

Global Non-invasive Prenatal Testing (NIPT) Market: Market Potential

Sequenom Inc., a key player operating in the NIPT market has recently announced the enhancement of MaterniT® GENOME laboratory-developed test that identifies 1 in 3 positive findings that may not be detected by standard NIPT. While standard NIPTs can identify chromosomal abnormalities such as trisomies 21,13, 18, and chromosome aneuploidies, the MaterniT® GENOME can analyze all chromosomes for gains and losses of chromosomal materials that are 7 Megabases or greater in size. In fact it can also analyze microdeletions, which are less than 7 Megabases.

Efforts such as this by key players are expected to create growth potential for the global non-invasive prenatal testing market. Furthermore, untapped markets in emerging nations are projected to offer growth opportunities to players in the NIPT market.

Global Non-invasive Prenatal Testing (NIPT) Market: Regional Outlook

While North America has been leading in the global non-invasive prenatal testing owing to the presence of key players in the U.S. coupled with high awareness levels about NIPT, Europe is anticipated to emerge second in terms of leading. Moreover, Asia Pacific is anticipated to be the region witnessing the fastest growth, with countries such as China, Australia, India, and Japan holding great potential for growth in the NIPT market. A growing number of women preferring late pregnancy in the region is anticipated to be the driving force for the growth of the Asia Pacific non-invasive prenatal market. BGI Diagnostics and Berry Genomics are two of the leading companies operating in the NIPT market in China, which has pushed the growth of country. Moreover, the CFDA approval for BambniTest has propelled the growth of the market in this region.

Read Comprehensive Overview of Report @

https://www.tmrresearch.com/non-invasive-prenatal-testing-market

Global Non-invasive Prenatal Testing (NIPT) Market: Competitive Landscape

Illumina, Inc. (Verinata Health, Inc.), Sequenom, Inc., Ariosa Diagnostics, BGI Health, Natera, Inc., LabCorp, LifeCodexx AG, and Berry Genomics are the key players competing in the non-invasive prenatal testing market. By forming alliances with physician offices, hospitals, and clinical laboratories, these players operate by marketing their proprietary non-invasive prenatal tests.

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in today’s supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients’ conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

Email:[email protected]

#Non-invasive Prenatal Testing (NIPT) Market

0 notes